PMID- 34672822
OWN - NLM
STAT- MEDLINE
DCOM- 20240509
LR  - 20240509
IS  - 1942-7522 (Electronic)
IS  - 0145-5613 (Linking)
VI  - 103
IP  - 5
DP  - 2024 May
TI  - Diagnostic and Prognostic Value of Fibrinogen, Fibrinogen Degradation Products, 
      and Lymphocyte/Monocyte Ratio in Patients With Laryngeal Squamous Cell Carcinoma.
PG  - NP278-NP288
LID - 10.1177/01455613211048970 [doi]
AB  - OBJECTIVES: Laryngeal squamous cell carcinoma (LSCC) is a common squamous cell 
      carcinoma of the head and neck with no reliable diagnostic biomarkers. However, 
      recent studies have shown that inflammation plays an essential role in tumor 
      development, and several inflammation-based biomarkers have been shown to have 
      prognostic value. This study aimed to investigate the auxiliary value of 
      fibrinogen (FIB), fibrinogen degradation products (FDP), and lymphocyte/monocyte 
      ratio (LMR) in LSCC diagnosis and prognosis. METHODS: Clinical data from 218 
      patients recently diagnosed with LSCC and 207 diagnosed with benign laryngeal 
      lesions (BLLs) were retrospectively reviewed. Potential diagnostic biomarkers 
      were evaluated using univariate and multivariate analyses; receiver operating 
      characteristic (ROC) curve analysis was used to identify cut-off values and 
      diagnostic efficiency. Least absolute shrinkage and selection operator (LASSO) 
      Logistic regression analysis was used to screen for independent risk factors to 
      construct a diagnostic nomogram. The chi-squared test and Kaplan-Meier method 
      were performed to investigate the correlation of clinicopathological 
      characteristics and 3-year overall survival (OS) with FIB, FDP, and LMR in 
      patients with LSCC. RESULTS: FIB, FDP, and LMR levels were significantly 
      different between the LSCC and BLL groups (P < .001), and all were independent 
      risk factors for LSCC. The area under the ROC curve of the diagnostic nomogram 
      was .894. Additionally, FIB, FDP, and LMR were correlated with some invasive 
      clinicopathological features, and LMR >/=4.29 was associated with reduced OS (P = 
      .038). CONCLUSION: FIB, FDP, and LMR demonstrated potential as biomarkers for the 
      diagnosis and prognosis of LSCC; however, further studies are needed to confirm 
      their efficacy.
FAU - Han, Yanxun
AU  - Han Y
AD  - Department of Otolaryngology, Head and Neck Surgery, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, China. RINGGOLD: 36639
FAU - Ren, Zhiyao
AU  - Ren Z
AD  - Department of Breast Surgery, Department of General Surgery, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, China. RINGGOLD: 36639
FAU - Liu, Yuchen
AU  - Liu Y
AD  - Department of Otolaryngology, Head and Neck Surgery, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, China. RINGGOLD: 36639
FAU - Liu, Yehai
AU  - Liu Y
AUID- ORCID: 0000-0003-3977-2481
AD  - Department of Otolaryngology, Head and Neck Surgery, The First Affiliated 
      Hospital of Anhui Medical University, Hefei, China. RINGGOLD: 36639
LA  - eng
PT  - Journal Article
DEP - 20211021
PL  - United States
TA  - Ear Nose Throat J
JT  - Ear, nose, & throat journal
JID - 7701817
RN  - 9001-32-5 (Fibrinogen)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Fibrin Fibrinogen Degradation Products)
SB  - IM
MH  - Humans
MH  - *Fibrinogen/analysis
MH  - *Laryngeal Neoplasms/blood/pathology/mortality/diagnosis
MH  - Male
MH  - Female
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Prognosis
MH  - *Monocytes
MH  - *Lymphocytes
MH  - *Biomarkers, Tumor/blood
MH  - *ROC Curve
MH  - *Carcinoma, Squamous Cell/blood/diagnosis/pathology
MH  - Fibrin Fibrinogen Degradation Products/analysis
MH  - Aged
MH  - Nomograms
MH  - Risk Factors
MH  - Kaplan-Meier Estimate
MH  - Squamous Cell Carcinoma of Head and Neck/blood/mortality/pathology/diagnosis
MH  - Lymphocyte Count
MH  - Adult
OTO - NOTNLM
OT  - biomarker
OT  - diagnosis
OT  - fibrinogen
OT  - laryngeal squamous cell carcinoma
OT  - prognosis
COIS- Declaration of Conflicting InterestsThe authors declared no potential conflicts 
      of interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2021/10/22 06:00
MHDA- 2024/05/09 14:26
CRDT- 2021/10/21 20:40
PHST- 2024/05/09 14:26 [medline]
PHST- 2021/10/22 06:00 [pubmed]
PHST- 2021/10/21 20:40 [entrez]
AID - 10.1177/01455613211048970 [doi]
PST - ppublish
SO  - Ear Nose Throat J. 2024 May;103(5):NP278-NP288. doi: 10.1177/01455613211048970. 
      Epub 2021 Oct 21.